key: cord-0768548-0500b5ir authors: Han, Xiucui; Xu, Pengfei; Ye, Qing title: Analysis of COVID‐19 vaccines: Types, thoughts, and application date: 2021-08-15 journal: J Clin Lab Anal DOI: 10.1002/jcla.23937 sha: 82dc4b8fae97d0d7837da80aeb2566774bb45669 doc_id: 768548 cord_uid: 0500b5ir OBJECTIVE: To deal with COVID‐19, various countries have made many efforts, including the research and development of vaccines. The purpose of this manuscript was to summarize the development, application, and problems of COVID‐19 vaccines. METHODS: This article reviewed the existing literature to see the development of the COVID‐19 vaccine. RESULTS: We found that different types of vaccines had their own advantages and disadvantages. At the same time, the side effects of the vaccine, the dose of vaccination, the evaluation of the efficacy, and the application of the vaccine were all things worth studying. CONCLUSION: The successful development of the COVID‐19 vaccine concerns almost all countries and people in the world. We must do an excellent job of researching the immunogenicity and immune reactivity of the vaccines. We hope this review can help colleagues at home and abroad. The design of the COVID-19 vaccines must take into account both humoral and cellular immunity. In addition, COVID-19 is mainly spread through the respiratory tract and contact, so the role of mucosal immunity in preventing viral infections should be paid more attention. The virus contains four structural proteins. They are Spike S protein, Envelope E protein, Membrane/matrix protein, and Nucleocapsid N protein. The S protein has two subsections, S1 and S2. The S protein binds to specific receptors, causing the virus to infect cells. [5] [6] [7] The neutralizing antibody against the S protein can block this process and prevent the virus from invading. 8 can also effectively stimulate T-cell immune response, so it is the most important target antigen for vaccine design. N and M proteins have also been shown to induce the body to produce an efficient cellular immune response. [9] [10] [11] SARS-CoV-2 is unusual for a respiratory virus that binds to a receptor, angiotensin-converting enzyme 2 (ACE2). ACE2 can be expressed in virtually all organs, but especially in the lungs, 12 gut, 13 and brain. 14 Therefore, unlike most respiratory viruses, SARS-CoV-2 has a wider biological distribution and may cause considerable damage outside the respiratory system. It adversely affects the genitourinary system, digestive system, circulatory system, and central nervous system. The universality of the distribution of ACE2 receptors leads to multiple changes in symptoms, such as dyspnea, headache, diarrhea, venous thromboembolism, and high blood pressure. 15 The S protein binds to ACE2 on cells to mediate infection. The S1 subunit contains the receptor-binding domain (RBD) and is responsible for initial attachment to the host cells through the ACE2 receptor, while the S2 subunit promotes viral fusion with cells to initiate infection. 16 The S protein is a frequent vaccine target as it is expected that antibodies binding to the correct epitope on the S protein may be neutralizing and block intercellular viral spread. 16 The vaccines currently under study can be roughly divided into the following categories. Different types of vaccines have their characteristics (Table 1 ). DNA vaccines can enter cells like viral infections and use the host protein translation system to generate target antigens. As an endogenous immunogen, it can induce humoral and cellular immune responses at the same time. Given the advantages of nucleic acid vaccines, DNA vaccines do not require live viruses, so safety is improved. DNA vaccines insert genes encoding foreign antigens into plasmids containing eukaryotic expression elements and then directly introduce the plasmids into humans or animals, allowing them to express antigen proteins in host cells and induce immune responses to prevent diseases. 17 The manufacturing process of plasmid DNA is relatively straightforward, and the double-strand DNA molecules are more stable than the virus and can be freeze-dried for long-term storage. DNA vaccine vaccination method limits its application. Since the vaccine is mainly distributed in the intercellular space after vaccination, only a very small amount can enter the cell to produce protein immunogen, so the immune effect is greatly reduced. The plasmid DNA vaccine's main prohibitory factor is the low transfection efficacy, which requires transfection modalities. For example, Inovio's COVID-19 vaccine candidate, INO-4800, uses a handheld electroporation device, CELLECTRA. 18 The vaccine will be injected intradermally along and an entire S1−S2 cleavage site. 21 One of the most explored viral vector options is the Adenovirus (Ad), currently being used by both CanSino and Oxford/ AstraZeneca. and use the host protein translation system to generate target antigens. It can induce humoral and cellular immune responses at the same time. DNA vaccines do not require live viruses. The manufacturing process of plasmid DNA is relatively straightforward, and the doublestrand DNA molecules are more stable than the virus and can be freeze-dried for longterm storage. mRNA vaccines mRNA vaccines need to enter the cytoplasm to achieve target antigens' expression theoretically safer The immune effect is not satisfactory, and a relatively high proportion of side effects. Non-replicating viral vector vaccines It can encode for the full-length S protein of SARS-CoV−2. The effectiveness of this vaccine is relatively high. It may not effective for people with recessive infectious viruses. Inactivated vaccines Inactivated vaccines are mainly obtained through three inactivation methods, which make it lose its infectivity and toxicity while maintaining immunogenicity. They are easy to prepare and can efficiently cause humoral immune responses. Vaccine production requires the operation of high concentrations of live viruses, which poses a certain biological safety risk. The T-cell immune response caused by inactivated vaccines is generally weak. The inactivated SARS-CoV−2 vaccine (Vero cells) Live attenuated vaccines Live attenuated vaccine reduces virus virulence through point mutation or deletion of crucial virus protein but does not affect its immunogenicity and replication ability. This vaccine program has very good immunogenicity and can induce systemic immunity and mucosal immune response, and the immunity is lasting. It is possible to restore virulence in the body due to retrograde mutations Polio vaccine The antigen protein of the pathogen is expressed and purified through genetic engineering to induce an immune response. Subunit vaccines are composed of purified recombinant proteins and are considered to be the safest vaccines. It has good safety and immunogenicity. As a non-endogenous antigen, subunit vaccines cannot be presented through MHC-I and cannot effectively produce sensitized cytotoxic T cells (CTL). Trained immunitybased vaccines Trained immunity-based vaccines can activate the adaptive immune system and provide pathogen-specific protection / The production standards of the BCG vaccine will be different. Adenovirus is common cold viruses with a double-stranded DNA genome. CanSino is using Ad type 5 (Ad5) and named the vaccine Ad5-nCoV. 22 Ad5-nCoV can encode for the full-length S protein of SARS-CoV-2. This gene is derived from the Wuhan-Hu-1 sequence of SARS-CoV-2 and is cloned into the E1-and E3-deleted Ad5 vector together with the tissue plasminogen activator signal peptide. 16 The effectiveness of this vaccine is relatively high, but the disadvantage is that it may not effective for people with recessive infectious viruses. Live attenuated vaccine reduces virus virulence through point mutation or deletion of crucial virus protein but does not affect its immunogenicity and replication ability. This vaccine program has very good immunogenicity and can induce systemic immunity and mucosal immune response, and the immunity is lasting. Several live attenuated vaccines have been on the market, including yellow fever, smallpox, measles, polio, mumps, rubella, and chickenpox. The SARS live attenuated vaccine will recover its virulence after continuous passage in cells or mice, suggesting that the vaccine scheme has a greater biological safety risk. 27 Without sufficient evidence to ensure that live attenuated vaccines will not regain strength, this strategy is not currently recommended for COVID-19 vaccine development. Subunit vaccines are composed of purified recombinant proteins and are considered to be the safest vaccines. There are currently several subunit vaccines on the market, including hepatitis B, hepatitis E, and human papillomavirus vaccines. SARS and MERS subunit vaccines can produce high-titer neutralizing antibodies in mice, and nasal or oral vaccination can also induce a mucosal immune response, thereby more effectively blocking the virus transmission through the respiratory tract. The data also prove the protective efficacy of mucosal vaccination better than intramuscular inoculation. [28] [29] [30] [31] However, as a non-endogenous antigen, subunit vaccines cannot be presented through MHC-I and cannot effectively produce sensitized cytotoxic T cells (CTL). Considering the key role of cellular immunity in clearing coronavirus infections, the subunit vaccine of COVID-19 is best used in conjunction with other platform vaccines. It is recommended to include nasal and oral mucosal vaccination routes to activate mucosal immune responses. Trained immunity-based vaccines can activate the adaptive immune system and provide pathogen-specific protection. 32, 33 Currently, Bacille Calmette-Guerin (BCG), a vaccine against tuberculosis, can induce trained immunity against COVID-19 and is currently undergoing clinical evaluation, which will take time to prove. 34 Even if the BCG vaccine is effective against COVID-19, it also faces unique challenges. That is, the production standards of the BCG vaccine will vary from country to country, and it is not clear whether certain quality standards are required to provide protection against COVID-19. 35 There are always various problems in the development of vaccines. Among them, the later application and evaluation of vaccines are particularly prominent. Many phase III studies failed because of incorrect identification of the dose that best balances safety and efficacy. 36 The vaccine also has adverse reactions such as redness, swelling, muscle pain, and fever. 38, 39 The strategic objectives of the COVID-19 vaccine roadmap formulated by WHO include a series of preferred and most basic requirements such as vaccine safety and effectiveness. 40 The preferred requirements for safety/reactogenicity include "safety and reactogenicity sufficient to provide a highly favorable benefit/risk profile in the context of the observed vaccine efficacy and only mild, transient related to adverse vaccination events without serious adverse events". The most basic requirements for safety/reactogenicity include the benefits of vaccines outweigh the potential safety hazards. The long-term results were a safety that is sufficient to provide highly favorable benefits/risk characteristics in the context of the observed vaccine efficacy and immunogenicity. There were no serious adverse events related to vaccination. The preferred requirements for effectiveness include the protection effectiveness in the population is at least 70%, and the same is true for the elderly. If it is an outbreak treatment, the protective effect must appear within two weeks and last for at least one year. The most basic requirements include the population's protective effect is at least about 50% for at least six months. Key Symptoms, 43 trialists have the latitude in selecting specific symptoms and severities to trigger virologic testing. It is important to define a common COVID-19 endpoint that can be used consistently across trials, not only to interpret results but also to facilitate trials' meta-analyses. It is very important to use a standard set of clinical endpoints for vaccine efficacy evaluation in all trials to conduct a unified and comprehensive assessment of benefits and risks support aggregated data to analyze the immunosurrogate endpoint. In any case, COVID-19 and severe COVID-19 should be important independent clinical endpoints to be evaluated in each vaccine efficacy trial. All participants should be followed up sufficiently to collect meaningful data to evaluate long-term protection against these two endpoints, especially the severe COVID-19. More endpoint counts are needed to quantify vaccine efficacy reliably. Considering that vaccine-induced decrease in the incidence of symptomatic SARS-CoV-2 infections may be accompanied by a shift toward more asymptomatic infections, the ability to evaluate vaccine efficacy against the asymptomatic infection endpoint in trial designs should be included. Preventive vaccines will control COVID-19 is justified by the impact of vaccines on preventing disability and death from infectious diseases. 44 If the epidemic situation is well controlled, and the future epidemic situation is mainly imported, entry and exit personnel should be the target of implementing the immunization strategy, and close contacts of entry personnel should be used as vaccinations. If it is confirmed that the COVID-19 vaccine has the effect of preventing or alleviating the symptoms of the disease on the exposed subjects, it is possible to consider adopting a post-exposure immunization strategy for close contacts of confirmed COVID-19 cases. Therefore, it is necessary to evaluate the protective effect of COVID-19 vaccines, especially vaccines developed by new technologies, to determine post-exposure vaccination's scientific nature. For subjects who may be exposed to COVID-19 patients or highrisk infections, such as medical staff in fever clinics, COVID-19 pathogen testing personnel, contact persons from COVID-19 endemic countries, etc., should take exposure pre-immune prevention strategies. In the event of a COVID-19 epidemic, under the premise of confirming the emergency immunization effect of the COVID-19 vaccine, an emergency immunization strategy can be considered for the population in the epidemic area. Therefore, in the early stage of vaccine marketing, it is necessary to carry out the effect evaluation of emergency immunization, especially the effect evaluation of the ring immunization strategy's implementation. In addition to the above four immunization strategies for pandemic immunization, because COVID-19 is susceptible to the entire population, this feature is different from the H1N1 pandemic. 49 In the case of vaccine supply in batches, comprehensive consideration of protection priorities, reducing deaths and cluster outbreaks determine the targets and immunization procedures for mass pandemic vaccination. In short, the successful development of the COVID-19 vaccine concerns almost all countries and people in the world. We must do an excellent job of researching the immunogenicity and immune reactivity of the vaccines. Not applicable. The authors declare no conflicts of interest. XCH designed the current study and was major contributors in writing the manuscript. PFX and QY were responsible for the modification and giving final approval of the manuscript. All authors read and approved the final manuscript. Data sharing is not applicable to this article as no new data were created or analyzed in this study. https://orcid.org/0000-0002-1630-4047 COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus Draft landscape of COVID-19 candidate vaccines Draft landscape of COVID-19 candidate vaccines Structure of SARS coronavirus spike receptor-binding domain complexed with receptor Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus MERS-CoV spike protein: a key target for antivirals Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice Induction of SARS-nucleoproteinspecific immune response by use of DNA vaccine Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus Angiotensin-converting enzyme 2 in lung diseases ACE2 expression by colonic epithelial cells is associated with viral infection Angiotensin-converting enzyme 2 in the brain: properties and future directions New understanding of the damage of SARS-CoV-2 infection outside the respiratory system Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity INOVIO Expands manufacturing of COVID-19 DNA vaccine INO-4800 With New Funding from CEPI Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials An mRNA Vaccine against SARS-CoV-2 -Preliminary Report Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-inhuman trial Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus Early immunoresponse of BALB/C mice to inactivated SARS vaccines prepared with different adjuvants Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirusvectored vaccines Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines A novel bacterium-like particle vaccine displaying the MERS-CoV receptor-binding domain induces specific mucosal and systemic immune responses in mice Antibody-mediated protection against MERS-CoV in the murine model Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection Trained immunitybased vaccines: a new paradigm for the development of broadspectrum anti-infectious formulations Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes BCG vaccine for health care workers as defense against COVID 19 (BADAS) Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation Advanced methods for dose and regimen finding during drug development: summary of the EMA/EFPIA workshop on dose finding Efficacy of highdose versus standard-dose influenza vaccine in older adults Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? Viruses World Health Organization. WHO target product profiles for COVID-19 vaccines National Medical Products Administration. Announcement on Issuing the Guidelines for the Classification Standards for Adverse Events in Clinical Trials of Preventive Vaccines Research on SARS vaccine and its related immune problems Food and Drug Administration, Center for Biologics Evaluation and Research. Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry. Accessed at www.fda.gov/media/ 13963 8/ down load on Review of immunization strategies and considerations for future immunization strategies with COVID-19 vaccines Ten Years in Public Health Early evidence of the effect of SARS-CoV-2 vaccine at one medical center SARS-CoV-2 infection after vaccination in health care workers in California BNT162b2 mRNA Covid-19 vaccine effectiveness among health care workers Comparison of epidemiological and clinical features of severe respiratory syndrome, pandemic influenza A (H1N1), and new coronavirus pneumonia and its enlightenment Analysis of COVID-19 vaccines: Types, thoughts, and application